Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NFS-07
- Development stage
- Preclinical
- Lead developer
- Neurophth
- Modality
- Gene Therapies
- Administration
- Ophthalmic
01
Overview
NFS-07 is a preclinical gene therapy candidate developed by Neurophth (Wuhan Kaidejinuo Biotechnology). It utilizes a recombinant adeno-associated virus (AAV) vector to deliver a therapeutic genetic payload to target cells. While the specific molecular target and primary indication remain undisclosed by the developer, Neurophth specializes in the development of gene therapies for ophthalmic conditions, including Leber hereditary optic neuropathy (LHON), glaucoma, and age-related macular degeneration. The program is currently in the early research and preclinical stages of development, following the company's established platform for ocular gene delivery.
Beyond the preview
Go deeper on NFS-07.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NFS-07.